Gracell Biotechnologies Inc reports results for the quarter ended in December - Earnings Summary

Gracell Biotechnologies

14/03/2022 13:31

* Gracell Biotechnologies Inc  GRCL.OQ  reported a quarterly
adjusted loss of 30 cents​​ per share for the quarter ended in
December. The mean expectation of two analysts for the quarter
was for a loss of 33 cents per share.
    * Reported revenue was zero​;  analysts expected zero. 
    * Gracell Biotechnologies Inc's reported EPS for the quarter
was a
loss of 30 cents​.
    * The mean earnings estimate of analysts was unchanged in
the last
three months.​ 
    * In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
    * Gracell Biotechnologies Inc shares had fallen by 57.8%
this
quarter.
    * The company reported a quarterly loss of $20.18 million.
    * Wall Street's median 12-month price target for Gracell
Biotechnologies Inc is $33.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 

This summary was machine generated March 14 at 01:30 p.m.  ​All
figures in US dollars unless otherwise stated